Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 4/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | QSOX1 | O00391 | 1/20 | 0.73 |
| ▸ | RGS12 | O14924 | 1/20 | 0.73 |
| ▸ | PMM2 | O15305 | 1/20 | 0.73 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.73 |
| ▸ | GMNN | O75496 | 1/20 | 0.73 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | CYBB | P04839 | 1/20 | 0.73 |
| ▸ | BCHE | P06276 | 1/20 | 0.73 |
| ▸ | GLA | P06280 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ebselen SCHEMBL29370082 | 0.85 | METAP2 (1.00) | METAP2HDAC6NPSR1KDM4EMEN1 | |
| Ebselen SCHEMBL4406056 | 0.85 | METAP2 (1.00) | METAP2HDAC6NPSR1KDM4EMEN1 | |
| Ebselen SCHEMBL33829 | 0.85 | METAP2 (1.00) | METAP2HDAC6NPSR1KDM4EMEN1 | |
| Ebselen SCHEMBL20678555 | 0.83 | METAP2 (0.96) | METAP2HDAC6NPSR1KDM4EMEN1 | |
| Ebselen SCHEMBL19064566 | 0.83 | METAP2 (0.96) | METAP2HDAC6NPSR1KDM4EMEN1 | |
| Ebselen SCHEMBL20477111 | 0.83 | METAP2 (0.96) | METAP2HDAC6NPSR1KDM4EMEN1 | |
| SCHEMBL1906347 | 0.82 | HDAC6 (0.69) | METAP2HDAC6NPSR1KDM4EMEN1 | |
| SCHEMBL5885139 | 0.82 | METAP2 (0.74) | METAP2HDAC6NPSR1KDM4EMEN1 | |
| SCHEMBL193047 | 0.82 | METAP2 (0.79) | METAP2HDAC6NPSR1KDM4EMEN1 | |
| SCHEMBL28783439 | 0.80 | METAP2 (0.77) | METAP2HDAC6NPSR1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255731-A | Synthesis method of biguanide derivative | 湖北玖天生物医药科技有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118255731-A | Synthesis method of biguanide derivative | 湖北玖天生物医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20230330238-A1 | CHIMERIC CONJUGATES FOR DEGRADATION OF VIRAL AND HOST PROTEINS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2021-05-25 | — | — | US | disclosed |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-03-04 | — | — | US | disclosed |
| US-20190307726-A1 | PHARMACEUTICAL FORMULATIONS | MOLECULAR DEFENSES CORP (US) | 2019-10-10 | — | — | US | disclosed |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2018-08-28 | — | — | US | disclosed |
| WO-2017091737-A1 | PHARMACEUTICAL FORMULATIONS | Molecular Defenses Corporation (US) | 2017-06-01 | — | — | WO | disclosed |
| US-9085598-B2 | Compounds targeting the cell invasion protein complex, their pharmaceutical compositions and methods of use thereof | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2015-07-21 | — | — | US | disclosed |
| US-20140256659-A1 | Compounds Targeting the Cell Invasion Protein Complex, Their Pharmaceutical Compositions and Methods of Use Thereof | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256659-A1 | Compounds Targeting the Cell Invasion Protein Complex, Their Pharmaceutical Compositions and Methods of Use Thereof | PTK2, ILK, CTTN | METAP2 2193/4885HDAC6 545/4885NPSR1 3606/4885 |
| US-20190307726-A1 | PHARMACEUTICAL FORMULATIONS | GSS, GSR, MGST3 | METAP2 1129/4885HDAC6 1379/4885NPSR1 631/4885 |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | NOX1, NOX3, NOX4 | METAP2 990/4885HDAC6 699/4885NPSR1 1815/4885 |
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | SELENOI, TST, SCLY | METAP2 1704/4885HDAC6 823/4885NPSR1 3296/4885 |
| US-20230330238-A1 | CHIMERIC CONJUGATES FOR DEGRADATION OF VIRAL AND HOST PROTEINS AND METHODS OF USE | MDM2, TP53, USP19 | METAP2 263/4885HDAC6 695/4885NPSR1 1712/4885 |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | SELENOI, TST, GSS | METAP2 2771/4885HDAC6 1247/4885NPSR1 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.